| |
Fig. S3. SMAD1 inhibition during cardiac chamber differentiation does not affect expression of the cardiac markers tropomyosin and Tbx5. (A,B) In situ hybridization for Tbx5 on stage 40 DMSO (A) and dorsomorphin-treated (B) anterior explants shows normal expression of Tbx5 in the heart and cardinal vein after SMAD1 inhibition. (C-F) Whole-mount antibody staining for tropomyosin of a stage 40 DMSO (C,E) or dorsomorphin-treated (D,F) anterior explants. Ventral view reveals no change in expression of tropomyosin in the heart after treatment with dorsomorphin. Dorso, dorsomorphin. Scale bars: 1 mm.
|
